Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094675 | 0.90 | MAP4K4 (0.46) | ST14F2 | |
| SCHEMBL6971958 | 0.80 | F2 (0.42) | F2F10PLG | |
| SCHEMBL6093293 | 0.74 | F2 (0.46) | F2F10PLG | |
| SCHEMBL6964921 | 0.71 | F2 (0.41) | F2F10PLG | |
| SCHEMBL6092150 | 0.68 | TSHR (0.63) | — | |
| SCHEMBL4969268 | 0.68 | NPSR1 (0.50) | DHFR | |
| SCHEMBL8222070 | 0.67 | DHFR (0.57) | DHFR | |
| SCHEMBL6092574 | 0.67 | XIAP (0.44) | F2F10PLG | |
| SCHEMBL4381414 | 0.67 | HTT (0.49) | — | |
| SCHEMBL7072382 | 0.66 | DHFR (0.51) | DHFRPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | claimed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | ST14 1087/4885DHFR 640/4885HCRTR1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.